Current Landscape of Hydroxamic Acid Hybrids With Anti-Colorectal Cancer Potential

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Yanjing Cheng, Yafei Zhuang, Ni Zhu, You Yu, Meichun Hu
{"title":"Current Landscape of Hydroxamic Acid Hybrids With Anti-Colorectal Cancer Potential","authors":"Yanjing Cheng,&nbsp;Yafei Zhuang,&nbsp;Ni Zhu,&nbsp;You Yu,&nbsp;Meichun Hu","doi":"10.1002/ardp.70066","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Colorectal cancer, also referred to as colon cancer, is a malignant tumor originating from the inner lining of the rectum or colon, the longest segment of the large intestine. As one of the most prevalent digestive system cancers globally, colorectal cancer ranks third among all cancers worldwide, comprising approximately 10% of all new cancer cases, and poses a serious threat to human life and health. Hydroxamic acid hybrids as potential histone deacetylase (HDAC) inhibitors could exert anti-colorectal cancer effects through multiple interconnected pathways, primarily targeting key molecular and cellular processes involved in tumor growth, progression, and metastasis. Moreover, hydroxamic acid hybrids can simultaneously target two or more distinct cancer sites, thereby potentially enhancing therapeutic efficacy, overcoming drug resistance, improving pharmacokinetic properties, and minimizing side effects. This review outlines the current landscape of hydroxamic acid hybrids with potential anti-colorectal cancer properties, developed from 2020 to the present, aiming to open new avenues for exploring novel candidates.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 7","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70066","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer, also referred to as colon cancer, is a malignant tumor originating from the inner lining of the rectum or colon, the longest segment of the large intestine. As one of the most prevalent digestive system cancers globally, colorectal cancer ranks third among all cancers worldwide, comprising approximately 10% of all new cancer cases, and poses a serious threat to human life and health. Hydroxamic acid hybrids as potential histone deacetylase (HDAC) inhibitors could exert anti-colorectal cancer effects through multiple interconnected pathways, primarily targeting key molecular and cellular processes involved in tumor growth, progression, and metastasis. Moreover, hydroxamic acid hybrids can simultaneously target two or more distinct cancer sites, thereby potentially enhancing therapeutic efficacy, overcoming drug resistance, improving pharmacokinetic properties, and minimizing side effects. This review outlines the current landscape of hydroxamic acid hybrids with potential anti-colorectal cancer properties, developed from 2020 to the present, aiming to open new avenues for exploring novel candidates.

具有抗结直肠癌潜力的羟肟酸杂合体的现状
结直肠癌,也称为结肠癌,是一种起源于直肠或结肠内壁的恶性肿瘤,直肠或结肠是大肠最长的一段。结直肠癌是全球最常见的消化系统癌症之一,在全球所有癌症中排名第三,约占所有新发癌症病例的10%,对人类的生命和健康构成严重威胁。羟肟酸杂种作为潜在的组蛋白去乙酰化酶(HDAC)抑制剂,可以通过多种相互关联的途径发挥抗结直肠癌的作用,主要针对肿瘤生长、进展和转移的关键分子和细胞过程。此外,羟肟酸混合物可以同时靶向两个或多个不同的癌症部位,从而潜在地提高治疗效果,克服耐药性,改善药代动力学性质,并最大限度地减少副作用。本文概述了从2020年到现在具有潜在抗结直肠癌特性的羟肟酸杂合体的现状,旨在为探索新的候选药物开辟新的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信